2024-517511-70-00招募中1 期
A study to assess the effects of efgartigimod on emasiprubart in healthy adult participants
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Argenx
- 入组人数
- 81
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Chief Scientific Officer
Scientific
Argenx
研究点 (1)
Loading locations...
相似试验
招募中
2 期
A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem)2023-510216-39-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.69
招募中
3 期
A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravisOcular Myasthenia Gravis2024-514133-38-00Argenx163
招募中
不适用
Real-World Efgartigimod Effectiveness in CIDP: A Prospective StudyCIDPNCT07264426argenx200
尚未招募
不适用
A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjogren's Syndrome (PSjD)jRCT2031240584argenx BV30
已完成
3 期
A phase 2/3 study of efgartigimod PH20 SC in adult participants with bullous pemphigoid2023-508645-40-00Argenx90